Monday, March 13, 2017

Gorsuch Might Be Tough to Predict on Criminal Justice Cases

BY SAM HANANEL
ASSOCIATED PRESS

WASHINGTON (AP) — Judge Neil Gorsuch wasn’t convinced that a teenager who made burping sounds in a classroom should be arrested, handcuffed and taken to juvenile detention in a police car.

Gorsuch said the 13-year-old student from Albuquerque, New Mexico, should have been able to sue the arresting officer for excessive force. His powerful dissent in the case last year offers a glimpse of how Gorsuch – a favorite among conservatives – might be hard to pigeonhole on criminal justice issues if he is confirmed to the Supreme Court.

“Arresting a now compliant class clown for burping was going a step too far,” Gorsuch wrote, saying there is a difference “between childish pranks and more seriously disruptive behaviors.”

During a decade on the federal appeals court in Denver, Gorsuch has raised concerns about intrusive government searches and seizures that he found to violate constitutional rights. He generally has ruled against defendants appealing their convictions and those who claim they received unfair trials. But he also has warned in writings and speeches about the danger of having too many criminal laws on the books.

“What happens to individual freedom and equality when the criminal law comes to cover so many facets of daily life that prosecutors can almost choose their targets with impunity?” he said in a 2013 speech.

That skepticism seems to align him with the late Justice Antonin Scalia, a strong believer in protecting people from overzealous police and prosecutors. Scalia at times sided with liberals in tossing out evidence that breached privacy rights and in strengthening the right to confront accusers in court.

Liberal groups are opposing Gorsuch’s nomination, in part based on views that his overall record on criminal justice is too harsh.

“At a time when the abuses of our criminal justice system are becoming a national crisis, we cannot confirm a justice who does not understand the role of the Supreme Court to protect the most vulnerable among us,” said a report from People for the American Way, a liberal advocacy group.

When Gorsuch has said there are too many criminal laws, he has often focused on business regulations, such as requirements that mattress sellers preserve mattress tags or that lobster importers use cardboard instead of plastic.

Adam Winkler, a law professor at UCLA School of Law, says such decisions could forecast that Gorsuch may be a vote to curtail criminal prosecution of Wall Street executives and financiers.

“He is likely to read federal criminal laws narrowly,” Winkler said. “Gorsuch is also likely to favor industry against what he sees as excessive criminal laws regulating business.”

Some of his opinions have faulted police for seizing evidence in violation of the Fourth Amendment, which bars unreasonable searches. In a case last year, Gorsuch parted from the two-judge majority in a ruling that said police had a right to walk onto a man’s property to knock on the front door even though there were several “No Trespassing” signs in the yard.

Gorsuch mocked the majority’s opinion, saying it gave government agents the right to “invade” a homeowner’s property “whatever the homeowner may say or do about it.”

The homeowner “might add a wall or a medieval-style moat, too,” Gorsuch wrote. “Maybe razor wire and battlements and mantraps besides. Even that isn’t enough to revoke the state’s right to enter.”

In a separate 2016 case, Gorsuch was on a panel that found the National Center for Missing and Exploited Children violated the Fourth Amendment when it searched a man’s emails without a warrant and discovered child pornography. The emails had been forwarded by AOL, the man’s internet service provider, after the images were flagged by an automatic filter.

Writing for the panel, Gorsuch said the center is a government-like entity “endowed with law enforcement powers beyond those enjoyed by private citizens.” The case was sent back to a lower court to decide whether the search still might be reasonable on other grounds.

Paul Rothstein, a professor at Georgetown University Law Center, said Gorsuch appears to have a mixed record in criminal cases and “seems to call them as he sees them.”

“I think his primary area of concern for the citizen is in the privacy of your home or your private belongings,” Rothstein said. “He believes there is a private area and he’s pretty strong about that.”

Gorsuch has been less sympathetic to defendants in other rulings.

In a 2012 case, Gorsuch dissented from a majority opinion in which his colleagues sided with an Oklahoma man seeking to overturn his murder conviction due to an ineffective lawyer. The lawyer had advised his client to reject a plea agreement that called for a 10-year sentence. Instead, the man went to trial, was convicted and sentenced to life in prison.

The majority said the lawyer’s decision to reject the plea had “disastrous results” for his client. But Gorsuch said the man’s right to effective representation was not violated because he was later convicted in a fair trial.

In 2013, Gorsuch wrote a majority opinion ruling that a police officer did not use excessive force when he shot a man in the head with a stun gun during a chase. The man, who was suspected of growing marijuana plants and fleeing from police, later died. The officer said the suspect reached for his pocket despite warnings not to do so. A dissenting judge noted that the officer’s training manual specifically warned against aiming a stun gun at the head unless necessary.

Gorsuch said the situation facing the officer at the time was “replete with uncertainty and a reasonable officer in his shoes could have worried he faced imminent danger from a lethal weapon.”

You can keep up with all of HIGH TIMES’ news right here.



from http://ift.tt/2mEmZDy
by Associated Press at High Times

Capitalist Plot Seen Behind Canadian Cannabis Raids

Canada’s prince and princess of pot, activist-entrepreneurs Marc and Jodie Emery, have been charged with multiple trafficking-related counts, following the March 9 raids on their Cannabis Culture outlets in Vancouver, Toronto and Hamilton, Ont. 

CBC News reports that the duo face multiple charges including drug trafficking, possession for the purpose of trafficking, and conspiracy. Jodie Emery reacted to the busts by calling out the Trudeau government for hypocrisy.

She told Canada’s Global News: “If this is legalization, then Justin Trudeau lied to the Canadian people. This is a new form of prohibition.”

She urged Canadians to call Prime Minister Trudeau and “ask why we’re seeing more people being harmed under our so-called legalization than we ever saw under [ex-PM] Stephen Harper’s anti-marijuana policies.”

She went on to pose a big-money power-play behind the raids: “This is about protecting the corporate profits of stock-market businesses. They have sent the police to arrest peaceful people to protect their own financial interest… Shame on the Toronto Police Service and the Toronto city government for harming peaceful people.”

Just before the busts, the Toronto Globe & Mail reported that stocks in Canadian canna-businesses had been diving recently, as Trudeau’s legalization czar Bill Blair continues to say that Ottawa won’t rush into legalization.

Blair, the former Toronto police chief, confirmed that a bill is due in parliament this spring—but was quick to emphasize that working out a regulatory framework would be a lengthy process, even after the bill passes. (This despite Trudeau’s campaign promise that there would be legal cannabis in Canada “right away.”)

But perversely, Canada’s Financial Post reported that stocks in publicly-traded cannabis companies actually took a bounce after the Emery couple and three associated were arrested. The day after the news broke, Canopy Growth Corp closed nearly six percent higher on the Toronto Stock Exchange at $11.07. Aphria Inc was up six percent to close at $6.67, while Aurora Cannabis also rose six percent to close at $2.41.

The new Emery case could determine what the future of Canada’s cannabis industry will look like.

Dispensaries like the Cannabis Culture chain currently operate in a “grey area—technically illegal at the federal level, but formally or informally tolerated by some local authorities. It remains to be seen if Canada’s legalization regime will provide more elbow room for dispensaries, or if the licensed producers created for the national medical marijuana system will also come to dominate the recreational market.

Contacted for comment, David Malmo-Levine, the Vancouver-based activist who challenged cannabis prohibition in Canada’s courts, told HIGH TIMES: “The LPs are in direct competition with the dispensaries—and the dispensaries have advantages: 1) you can inspect and smell the pot before you buy, 2) you can ask the bud-tenders unlimited questions (and they have smoked it all so they can tell give you good information) and 3) there’s less bullshit—some dispensaries (like Cannabis Culture) just ask for ID and nothing else.”

Malmo-Levine owns the Stressed & Depressed dispensary, one of several slated to come under official regulation by Vancouver city authorities. But the judge in the Emery case has issued a formal order that the couple cease operation of Cannabis Culture.

You can keep up with all of HIGH TIMES’ marijuana news right here.



from http://ift.tt/2nmonJl
by Bill Weinberg at High Times

These Are the Best—and the Worst—States for Medical Marijuana

On paper, medical marijuana is more common in America than firearms.

Forty-four states have medical cannabis laws on the books—which means that more than 300 million Americans can access legal marijuana in some form if they or a family member is sick. That’s 85 percent of the country.

Compare that to the owners of the country’s 300 million guns—which are stashed in only one-third of households—and it seems the U.S. should be in the running for mellowest place on earth, rather than the best-armed and most-incarcerated.

And since deaths related to opiate abuse are reduced by as much as 25 percent where medical-marijuana is available, America should also expect the heroin epidemic to be ending any day now.

Sounds great! But for now, this is all abstract theory.

In practice, most medical-marijuana laws are crap and don’t really provide any marijuana at all—to sick people or anyone else, according to Americans for Safe Access, a national medical-cannabis advocacy group. So those 128,000 annual deaths due to prescription medication abuse won’t be ending anytime soon.

Americans for Safe Access (ASA) recently weighed all 44 medical-marijuana laws, and found nearly all of them wanting. Sixteen states—all of which allow non-psychoactive CBD-rich, low-THC oil only, and, in places, including Texas, which have yet to start delivering even this to patients—received a grade of F-minus from ASA for their bang-up jobs providing plant material to sick people, meaning they may as well have not even bothered.

More than 90 percent of Americans tell pollsters they support medical marijuana. Even Donald Trump has nothing bad to say about giving cannabis to people with AIDS or cancer. During Barack Obama’s time in the White House, the number of states that allow full-THC cannabis more than doubled from 13 states to 29. Fueled by dramatic anecdotes about CBD’s power to solve epileptic seizures and other serious intractable diseases, another 15 states have CBD-only laws.

ASA estimates there are two million medical marijuana patients nationwide. That number sounds awfully small—and many more Americans would probably be patients, if they could qualify. Five percent of Californians used medical marijuana in the last year, according to a survey, yet that number dips to well below one percent nationally.

One reason why is the near-impossible hoops most states force medical marijuana patients to jump though.

According to ASA:

“[M]any programs like Massachusetts and Maryland are experiencing long delays in licensing medical cannabis businesses to serve patients. A significant portion of these programs are not meeting the needs of their medical cannabis patients. In fact, when ASA surveyed patients, we found that less than a third of patients were satisfied with their program, less than 12% of patients considered their medicine to be affordable in states where there are dispensaries, and fewer than 20% of patients thought there was a sufficient number to serve them, with half reporting that they had to drive more than 20 miles to gain access.”

Imagine if half the country was a half-hour drive away from the nearest pharmacy. They might almost be ready for health-care reform.

California was deemed the best state in the country for medical-marijuana access, mostly for ease of access, but did not escape criticism. California’s cannabis supply was docked for having a low bar for product safety, an issue highlighted by recent reports of patients sickened and, in one case, dead thanks to contaminated cannabis.

Other states with workable medical marijuana programs include states with commercial dispensaries like Arizona, Colorado, Oregon and Washington.

Take a look at the report yourself, and ask yourself: Is it easier for you to buy a gun than it is to buy some legal weed? If it is, call your local lawmakers and start to complain. Justifiably. 

You can keep up with all of HIGH TIMES’ marijuana news right here.



from http://ift.tt/2mSJipz
by Chris Roberts at High Times

High Buy: EZ Does It

This post is sponsored by The Kind Pen.

EZ Does It
$9.99
Thekindpen.com

EZ1

Toking on the go can be a complicated process. Not so with the incredibly affordable and portable EZ Pipe from The Kind Pen. It’s a discreet and windproof pipe that’s virtually smokeless and comes equipped with a pop-up mouthpiece and a poker. With a built-in compartment that fits most brands of lighters, the EZ Pipe provides everything you need to fire up a bowl one-handed anywhere—and all in one simple and compact unit.

Simply pack the magnetically-secured stainless-steel bowl with ground-up material, spin the lid to cover the top and light her up to inhale tasty hit after hit, no matter where you may roam.

EZ Pipe also has the added benefit of conserving your herbs. The small intake hole only allows a certain amount of flame into the bowl, so you can avoid scorching the contents, avoiding harshness and preserving the flavor of your terpenes and other essential oils. It tastes so much better than any bat or one-hitter and is super easy to clean.  

EZ2

The EZ Pipe also costs less than $10, making it perfect for festivals, camping, hiking or a stony trip to the beach. They’re available in a wide variety of different colors, and because they’re so cheap, the EZ Pipe is practically disposable if necessary. Pick up a half dozen or more to use as gifts or for almost any occasion that demands discretion.

Follow The Kind Pen on Facebook/thekindpen and IG @thekindpen. And make sure to visit thekindpen.com to get your own EZ Pipe for only $9.99.

RELATED: Hot Pot Products: Must-Have Items for Cultivators and Connoisseurs



from http://ift.tt/2mjKDBz
by Danny Danko at High Times

Trump’s Choice for FDA Has Ties to Wall Street, Drug Makers

BY DARLENE SUPERVILLE AND LAURAN NEERGAARD
ASSOCIATED PRESS

WASHINGTON (AP) — A conservative doctor-turned-pundit with deep ties to Wall Street and the pharmaceutical industry is President Donald Trump’s pick to lead the Food and Drug Administration.

Dr. Scott Gottlieb would be tasked with Trump’s goal of cutting red tape at the FDA, which regulates everything from pharmaceuticals to seafood to electronic cigarettes. Trump has called the FDA’s drug approval process “slow and burdensome” despite changes to speed reviews, particularly of cutting-edge products.

Gottlieb, 44, is no stranger to the FDA – he served as a deputy commissioner under President George W. Bush. While he has frequently criticized the FDA for unnecessary regulations and urged changes to get safe and effective drugs onto the market faster, he generally has supported its overall mission.

A Senate vote is required before Gottlieb can take over as head of the agency.

Gottlieb is a resident fellow at the conservative American Enterprise Institute and a partner in the venture capital firm New Enterprise Associates. He has spent more than a decade in Washington rotating between the worlds of government, health policy consulting and political think tanks.

Since leaving the FDA in 2007, Gottlieb has served as a board member or adviser to at least nine pharmaceutical or medical technology companies, according to his LinkedIn profile. Gottlieb is a consultant to GlaxoSmithKline’s product investment board; a managing director at T.R. Winston & Company merchant bank, which specializes in health care; and a clinical assistant professor at New York University School of Medicine. He also is a policy adviser to the National Coalition for Cancer Survivorship.

There are likely to be questions at his Senate confirmation hearing about how those ties might affect his decisions at the FDA.

Federal ethics rules do not require government officials to sell off their investments, but they must recuse themselves from matters that would affect those investments. As part of the federal vetting process, FDA nominees typically disclose and sell stocks, funds and other investments that could pose a financial conflict of interest.

Gottlieb generally supports reduced FDA regulation, particularly for emerging products like health apps and wearable devices like the Apple Watch. But he has never embraced libertarian-leaning proposals that would have the FDA abandon its effectiveness reviews of drugs and medical products. Under those plans, the FDA would simply approve products that appear safe, allowing the private sector to determine how well they actually treat diseases or medical conditions.

Rep. Rosa DeLauro, D-Conn., who serves on the House Appropriations subcommittee that oversees FDA funding, said the nomination sends the message that Trump is committed to “rolling back regulations and opening the floodgates to potentially dangerous drugs and medical devices.”

The evaluation of medical effectiveness has been a cornerstone of the FDA’s mission since the early 1960s and is universally embraced by its staff and the businesses it regulates.

“If FDA were not in business of evaluating effectiveness then these companies wouldn’t be able to say much. Where companies distinguish themselves is by being able to claim that their product actually does something,” said Michael Gaba, an industry attorney who specializes in FDA law.

You can keep up with all of HIGH TIMES’ news right here.



from http://ift.tt/2nm0H7N
by Associated Press at High Times

Sunday, March 12, 2017

STRAIN OF THE DAY 03/13/2017: BLUE THAI (HYBRID)

CANNABIS STRAIN OF THE DAY 03/13/2017: BLUE THAI (HYBRID)

from http://ift.tt/2mgT41x
by Potbox, Inc.

Why a Good Smoke Session Is the Ultimate Bonding Experience

There's no single better way to bond with someone than smoking with them. Nothing brings people together like cannabis.

The post Why a Good Smoke Session Is the Ultimate Bonding Experience appeared first on Leafly.



from http://ift.tt/2lQouiV
by Dante Jordan at Leafly